Upadacitinib monotherapy versus methotrexate monotherapy in patients with rheumatoid arthritis: efficacy and safety through 5 years in the SELECT-EARLY randomized controlled trial

医学 中止 类风湿性关节炎 甲氨蝶呤 内科学 不利影响 随机对照试验
作者
Ronald van Vollenhoven,Vibeke Strand,Tsutomu Takeuchi,Nilmo Chávez,Pablo Mannucci Walter,Atul Singhal,Jerzy Świerkot,Nasser Khan,Xianwei Bu,Yihan Li,S. Penn,Heidi S. Camp,Jacob Aelion
出处
期刊:Arthritis Research & Therapy [Springer Nature]
卷期号:26 (1)
标识
DOI:10.1186/s13075-024-03358-x
摘要

Abstract Background To evaluate the efficacy and safety of upadacitinib monotherapy versus methotrexate (MTX) monotherapy over 5 years among MTX-naïve patients with moderately to severely active rheumatoid arthritis (RA) in the long-term extension (LTE) of the phase 3 SELECT-EARLY trial. Methods Patients were randomized to receive upadacitinib 15 mg or 30 mg or MTX. Patients who did not achieve CDAI remission and had < 20% improvement in tender and swollen joint counts at week 26 received rescue therapy (addition of MTX in the upadacitinib group and addition of upadacitinib in the MTX group). Efficacy assessments were evaluated over 5 years and are reported as observed (AO) for patients who received continuous monotherapy with upadacitinib 15/30 mg or MTX and by randomized group applying non-responder imputation (NRI). Treatment-emergent adverse events (TEAEs) per 100 patient-years were summarized over 5 years. Results Of 945 patients randomized and treated, 775 (82%) completed week 48 and entered the LTE on study drug. Higher proportions of patients consistently achieved disease activity targets over 5 years with upadacitinib than MTX. In AO analyses, 53%/59% of patients attained CDAI remission with upadacitinib 15/30 mg versus 43% with MTX at week 260. NRI analyses showed better CDAI, DAS28(CRP), and ACR responses with upadacitinib relative to MTX at week 260 (all comparisons, nominal P < .001). Upadacitinib treatment also resulted in numerically greater inhibition of structural joint progression through week 260 compared to MTX. Most TEAEs, serious AEs, and AEs leading to discontinuation were numerically higher in patients receiving upadacitinib 30 mg. Rates of serious infections, herpes zoster, creatine phosphokinase elevation, nonmelanoma skin cancer, and neutropenia were numerically higher with upadacitinib than MTX. The observed safety profile of upadacitinib over 5 years was consistent with earlier trial results and integrated phase 3 safety analyses. Conclusions Upadacitinib showed better clinical responses versus MTX in patients with RA throughout the 5-year trial. Higher rates of several AEs were observed with upadacitinib, especially in the 30 mg group, compared to MTX. When used as monotherapy in MTX-naïve patients, the approved upadacitinib 15 mg dose showed better long-term efficacy versus MTX and an overall favorable benefit-risk profile. Trial registration NCT02706873.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
1秒前
由天与完成签到,获得积分10
1秒前
乐乐应助superyang采纳,获得10
1秒前
2秒前
顾矜应助Rita采纳,获得10
2秒前
3秒前
郭雨发布了新的文献求助10
3秒前
wallonce发布了新的文献求助10
4秒前
4秒前
feimengxia完成签到 ,获得积分10
5秒前
5秒前
6秒前
Akim应助韩小小采纳,获得10
7秒前
陈末应助呀12345采纳,获得10
7秒前
wsqg123发布了新的文献求助10
7秒前
王晓风发布了新的文献求助30
7秒前
469459442发布了新的文献求助10
8秒前
8秒前
asd发布了新的文献求助10
9秒前
10秒前
郭雨完成签到,获得积分10
11秒前
9209完成签到 ,获得积分10
11秒前
12秒前
13秒前
樊璐完成签到,获得积分20
13秒前
jevon应助wallonce采纳,获得10
15秒前
简单的幸福完成签到,获得积分10
15秒前
16秒前
yy发布了新的文献求助10
16秒前
心台应助cetomacrogol采纳,获得10
17秒前
千俞发布了新的文献求助10
18秒前
斯文败类应助wu采纳,获得10
18秒前
大模型应助青春奇谈采纳,获得10
19秒前
李爱国应助澈千子采纳,获得10
21秒前
香蕉觅云应助lalala采纳,获得10
21秒前
22秒前
22秒前
22秒前
香蕉觅云应助L同学采纳,获得10
23秒前
高分求助中
歯科矯正学 第7版(或第5版) 1004
Smart but Scattered: The Revolutionary Executive Skills Approach to Helping Kids Reach Their Potential (第二版) 1000
Semiconductor Process Reliability in Practice 720
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 700
Mesopotamian divination texts : conversing with the gods : sources from the first millennium BCE 500
The Heath Anthology of American Literature: Early Nineteenth Century 1800 - 1865 Vol. B 500
A new species of Velataspis (Hemiptera Coccoidea Diaspididae) from tea in Assam 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3223022
求助须知:如何正确求助?哪些是违规求助? 2871793
关于积分的说明 8177057
捐赠科研通 2538658
什么是DOI,文献DOI怎么找? 1370749
科研通“疑难数据库(出版商)”最低求助积分说明 645870
邀请新用户注册赠送积分活动 619832